News

Even if you don't recognize the name Viatris (NASDAQ: VTRS), you may have come in very close contact with this pharma company. It sells a wide variety of generic drugs -- such as generic Zyrtec

Even if you don't recognize the name Viatris (NASDAQ: VTRS), you may have come in very close contact with this pharma company. It sells a wide variety of generic drugs -- such as generic Zyrtec

A high-yielding dividend stock can generate lots of dividend income for your portfolio. But that doesn't mean you should buy a stock only because of its yield. Dividends are never guaranteed and

A high-yielding dividend stock can generate lots of dividend income for your portfolio. But that doesn't mean you should buy a stock only because of its yield. Dividends are never guaranteed and

Pfizer (NYSE: PFE) and Viatris (NASDAQ: VTRS) have a common past. That's because Viatris came about a few years ago when Pfizer's Upjohn business merged with generic drug giant, Mylan. Since, their

Pfizer (NYSE: PFE) and Viatris (NASDAQ: VTRS) have a common past. That's because Viatris came about a few years ago when Pfizer's Upjohn business merged with generic drug giant, Mylan. Since, their

Shares of Amarin (NASDAQ: AMRN) were sinking 22.7% as of 10:56 a.m. ET on Wednesday. The steep decline came after the drugmaker announced an organizational restructuring after the market close on

If you are looking for a high-yield dividend stock to boost your income, you might be interested in Altria (NYSE: MO) or Viatris (NASDAQ: VTRS). Both companies offer attractive dividend yields of

If you are looking for a high-yield dividend stock to boost your income, you might be interested in Altria (NYSE: MO) or Viatris (NASDAQ: VTRS). Both companies offer attractive dividend yields of

Buying shares of a generic drug manufacturer like Viatris (NASDAQ: VTRS) isn't the right move for everyone. While most investors would look for such companies to have a long history of bulletproof

Buying shares of a generic drug manufacturer like Viatris (NASDAQ: VTRS) isn't the right move for everyone. While most investors would look for such companies to have a long history of bulletproof

For a generic drugmaker like Viatris (NASDAQ: VTRS), big spurts of growth are unlikely. The market for low-cost generic medications is competitive, and success is largely defined by maintaining

For a generic drugmaker like Viatris (NASDAQ: VTRS), big spurts of growth are unlikely. The market for low-cost generic medications is competitive, and success is largely defined by maintaining

You can secure a 5% dividend yield without being too risky or aggressive. Sometimes, it's a matter of jumping on a good opportunity when it arises. A stock can fall in value for various reasons

You can secure a 5% dividend yield without being too risky or aggressive. Sometimes, it's a matter of jumping on a good opportunity when it arises. A stock can fall in value for various reasons

Companies that produce generic drugs aren't known for being exciting investments, and there's little chance they'll ever expand as fast as your average tech stock or most other growth stocks. If

Companies that produce generic drugs aren't known for being exciting investments, and there's little chance they'll ever expand as fast as your average tech stock or most other growth stocks. If

Image source: The Motley Fool.

Amarin Plc (NASDAQ: AMRN)Q1 2023 Earnings CallMay 03, 2023, 8:00 a.m. ET

Operator

Continue reading

Source Fool.com

Shares of Adaptimmune Therapeutics (NASDAQ: ADAP) were up as much as 9.7% early Tuesday after the clinical-stage biotech announced that it had reached an agreement with GSK (NYSE: GSK) to return the